Maxim Group analyst Jason McCarthy maintained a Buy rating on Athersys (ATHX) today and set a price target of $8. The company’s shares closed on Friday at $1.87.
McCarthy noted:
“Athersys reported 3Q18 (11/6) with revenue of $2.3M (license fees, grants, collaborative revenue, other) and a net loss of ($9.7M). The company ended the period with $48M in cash on the balance sheet.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 4.8% and a 37.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Athersys with a $8.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.09 and a one-year low of $1.29. Currently, Athersys has an average volume of 578.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas.
